REFERENCES
1. Wenger NK, Arnold A, Bairey Merz CN, et al. Hypertension across a woman's life cycle. J Am Coll Cardiol. 2018;71:1797-813.
2. Gerdts E, Sudano I, Brouwers S, et al. Sex differences in arterial hypertension. Eur Heart J. 2022;43:4777-88.
3. Macut D, Mladenović V, Bjekić-Macut J, et al. Hypertension in polycystic ovary syndrome: novel insights. Curr Hypertens Rev. 2020;16:55-60.
4. Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018;13:291-310.
5. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024;45:3912-4018.
6. Cho L, Kaunitz AM, Faubion SS, et al. Rethinking menopausal hormone therapy: for whom, what, when, and how long? Circulation. 2023;147:597-610.
7. Mangione CM, Barry MJ, Nicholson WK, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: US preventive services task force recommendation statement. JAMA. 2022;328:1740-6.
8. Heart Health Group of Chinese Society of Cardiology of Chinese Medical Association; Hypertension Group of Chinese Society of Cardiology of Chinese Medical Association. Expert consensus on blood pressure management in hypertensive disorders of pregnancy (2019). Chin J Cardiol. 2020;48:10.
9. Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis. Hypertens Res. 2017;40:213-20.
10. Kario K, Okura A, Hoshide S, Mogi M. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 2024;47:1099-102.
11. Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18:785-802.
12. Ghazi L, Annabathula RV, Bello NA, Zhou L, Stacey RB, Upadhya B. Hypertension across a woman's life cycle. Curr Hypertens Rep. 2022;24:723-33.
13. Chapman N, Ching SM, Konradi AO, et al. Arterial hypertension in women: state of the art and knowledge gaps. Hypertension. 2023;80:1140-9.
14. Ji H, Kim A, Ebinger JE, et al. Sex differences in blood pressure trajectories over the life course. JAMA Cardiol. 2020;5:19-26.
15. Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: results from the China hypertension survey, 2012-2015. Circulation. 2018;137:2344-56.
16. Tao S, Wu X, Duan X, et al. Hypertension prevalence and status of awareness, treatment and control in China. Chin Med J. 1995;108:483-9.
17. Xia S, Du X, Guo L, et al. Sex Differences in primary and secondary prevention of cardiovascular disease in China. Circulation. 2020;141:530-9.
18. Gerdts E, Regitz-Zagrosek V. Sex differences in cardiometabolic disorders. Nat Med. 2019;25:1657-66.
19. Drury ER, Wu J, Gigliotti JC, Le TH. Sex differences in blood pressure regulation and hypertension: renal, hemodynamic, and hormonal mechanisms. Physiol Rev. 2024;104:199-251.
20. MacRitchie AN, Jun SS, Chen Z, et al. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res. 1997;81:355-62.
21. Ng AV, Callister R, Johnson DG, Seals DR. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension. 1993;21:498-503.
22. Weitz G, Elam M, Born J, Fehm HL, Dodt C. Postmenopausal estrogen administration suppresses muscle sympathetic nerve activity. J Clin Endocrinol Metab. 2001;86:344-8.
23. White CR, Shelton J, Chen SJ, et al. Estrogen restores endothelial cell function in an experimental model of vascular injury. Circulation. 1997;96:1624-30.
24. Pilic L, Pedlar CR, Mavrommatis Y. Salt-sensitive hypertension: mechanisms and effects of dietary and other lifestyle factors. Nutr Rev. 2016;74:645-58.
25. Schulman I, Raij L. Salt sensitivity and hypertension after menopause: role of nitric oxide and angiotensin II. Am J Nephrol. 2006;26:170-80.
26. Schulman IH, Aranda P, Raij L, Veronesi M, Aranda FJ, Martin R. Surgical menopause increases salt sensitivity of blood pressure. Hypertension. 2006;47:1168-74.
27. Faulkner JL, Belin de Chantemèle EJ. Female sex, a major risk factor for salt-sensitive hypertension. Curr Hypertens Rep. 2020;22:99.
28. Kurniansyah N, Goodman MO, Kelly TN, et al. A multi-ethnic polygenic risk score is associated with hypertension prevalence and progression throughout adulthood. Nat Commun. 2022;13:3549.
29. Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated cardiovascular disease. Nat Rev Nephrol. 2018;14:185-201.
30. Bycroft C, Freeman C, Petkova D, et al. The UK biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203-9.
31. Sampson AK, Jennings GL, Chin-Dusting JP. Y are males so difficult to understand?: a case where “X” does not mark the spot. Hypertension. 2012;59:525-31.
32. Khan SI, Andrews KL, Jennings GL, Sampson AK, Chin-Dusting JPF. Y chromosome, hypertension and cardiovascular disease: is inflammation the answer? Int J Mol Sci. 2019;20:2892.
33. Arnold AP. Four core genotypes and XY* mouse models: update on impact on SABV research. Neurosci Biobehav Rev. 2020;119:1-8.
34. Ji H, Zheng W, Wu X, et al. Sex chromosome effects unmasked in angiotensin II-induced hypertension. Hypertension. 2010;55:1275-82.
35. Charchar FJ, Tomaszewski M, Padmanabhan S, et al. The Y chromosome effect on blood pressure in two European populations. Hypertension. 2002;39:353-6.
36. Hamidovic A, Van Hedger K, Choi SH, Flowers S, Wardle M, Childs E. Quantitative meta-analysis of heart rate variability finds reduced parasympathetic cardiac tone in women compared to men during laboratory-based social stress. Neurosci Biobehav Rev. 2020;114:194-200.
37. Philbois SV, Facioli TP, Gastaldi AC, et al. Important differences between hypertensive middle-aged women and men in cardiovascular autonomic control-a critical appraisal. Biol Sex Differ. 2021;12:11.
38. Sevre K, Lefrandt JD, Nordby G, et al. Autonomic function in hypertensive and normotensive subjects: the importance of gender. Hypertension. 2001;37:1351-6.
39. Cai C, Vandermeer B, Khurana R, et al. The impact of occupational shift work and working hours during pregnancy on health outcomes: a systematic review and meta-analysis. Am J Obstet Gynecol. 2019;221:563-76.
40. Coutinho T, Borlaug BA, Pellikka PA, Turner ST, Kullo IJ. Sex differences in arterial stiffness and ventricular-arterial interactions. J Am Coll Cardiol. 2013;61:96-103.
41. Campos-Arias D, De Buyzere ML, Chirinos JA, Rietzschel ER, Segers P. Longitudinal changes of input impedance, pulse wave velocity, and wave reflection in a middle-aged population: the asklepios study. Hypertension. 2021;77:1154-65.
42. McEniery CM, Yasmin
43. Nardin C, Maki-Petaja KM, Miles KL, et al. Cardiovascular phenotype of elevated blood pressure differs markedly between young males and females: the Enigma study. Hypertension. 2018;72:1277-84.
44. Mitchell GF. Aortic stiffness, pressure and flow pulsatility, and target organ damage. J Appl Physiol. 2018;125:1871-80.
45. Ji H, Niiranen TJ, Rader F, et al. Sex differences in blood pressure associations with cardiovascular outcomes. Circulation. 2021;143:761-3.
46. Society of Cardiology, Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. [Expert consensus on the management of hypertension in women]. Zhonghua Xin Xue Guan Bing Za Zhi. 2025;53:872-81.
47. Gillon TE, Pels A, von Dadelszen P, MacDonell K, Magee LA. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One. 2014;9:e113715.
48. Shan D, Qiu PY, Wu YX, et al. Pregnancy outcomes in women of advanced maternal age: a retrospective Cohort study from China. Sci Rep. 2018;8:12239.
49. Jafri S, Ormiston ML. Immune regulation of systemic hypertension, pulmonary arterial hypertension, and preeclampsia: shared disease mechanisms and translational opportunities. Am J Physiol Regul Integr Comp Physiol. 2017;313:R693-705.
50. Ngene NC, Moodley J. Postpartum blood pressure patterns in severe preeclampsia and normotensive pregnant women following abdominal deliveries: a cohort study. J Matern Fetal Neonatal Med. 2020;33:3152-62.
51. Goel A, Maski MR, Bajracharya S, et al. Epidemiology and mechanisms of de novo and persistent hypertension in the postpartum period. Circulation. 2015;132:1726-33.
52. Wu P, Jordan KP, Chew-Graham CA, et al. Temporal trends in pregnancy-associated stroke and its outcomes among women with hypertensive disorders of pregnancy. J Am Heart Assoc. 2020;9:e016182.
53. Graves M, Howse K, Pudwell J, et al. Pregnancy-related cardiovascular risk indicators: primary care approach to postpartum management and prevention of future disease. Can Fam Phys. 2019;65:883-9.
54. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:3165-241.
55. Cho L, Davis M, Elgendy I, et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:2602-18.
56. Casiglia E, d'Este D, Ginocchio G, et al. Lack of influence of menopause on blood pressure and cardiovascular risk profile: a 16-year longitudinal study concerning a cohort of 568 women. J Hypertens. 1996;14:729-36.
57. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020;142:e506-32.
58. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-34.
59. Nejati S, Zahiroddin A, Afrookhteh G, et al. Effect of group mindfulness-based stress-reduction program and conscious yoga on lifestyle, coping strategies, and systolic and diastolic blood pressures in patients with hypertension. J Tehran Heart Cent. 2015;10:140-8.
60. Räikkönen K, Matthews KA, Kuller LH. Trajectory of psychological risk and incident hypertension in middle-aged women. Hypertension. 2001;38:798-802.
61. Regitz-Zagrosek V, Gebhard C. Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes. Nat Rev Cardiol. 2023;20:236-47.
62. Vaccarino V, Wilmot K, Al Mheid I, et al. Sex differences in mental stress-induced myocardial ischemia in patients with coronary heart disease. J Am Heart Assoc. 2016:5.
63. Mendlowicz V, Garcia-Rosa ML, Gekker M, et al. Post-traumatic stress disorder as a predictor for incident hypertension: a 3-year retrospective cohort study. Psychol Med. 2023;53:132-9.
64. Fiechter M, Roggo A, Burger IA, et al. Association between resting amygdalar activity and abnormal cardiac function in women and men: a retrospective cohort study. Eur Heart J Cardiovasc Imaging. 2019;20:625-32.
65. Steiner M, Dunn E, Born L. Hormones and mood: from menarche to menopause and beyond. J Affect Disord. 2003;74:67-83.
66. Charchar FJ, Prestes PR, Mills C, et al. Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2024;42:23-49.
67. Bautista LE, Vera-Cala LM, Colombo C, Smith P. Symptoms of depression and anxiety and adherence to antihypertensive medication. Am J Hypertens. 2012;25:505-11.
68. Phillis C, Midenberg E, O'Connor M, Terry W Jr, Keel C, Noh P. Juxtaglomerular cell tumor: a rare presentation of a surgically curable cause of secondary hypertension in the pediatric population. Urology. 2021;156:e131-3.
69. Maiolino G, Battistel M, Barbiero G, Bisogni V, Rossi GP. Cure with cryoablation of arterial hypertension due to a renin-producing tumor. Am J Hypertens. 2018;31:537-40.
70. Inam R, Gandhi J, Joshi G, Smith NL, Khan SA. Juxtaglomerular cell tumor: reviewing a cryptic cause of surgically correctable hypertension. Curr Urol. 2019;13:7-12.
71. Szczepaniak P, Siedlinski M, Hodorowicz-Zaniewska D, et al. Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism. J Clin Invest. 2022;132:e149117.
72. Rillamas-Sun E, Kwan ML, Iribarren C, et al. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Breast Cancer Res Treat. 2023;201:117-26.
73. Colleoni M, Luo W, Karlsson P, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:127-38.
74. Kwan ML, Cheng RK, Iribarren C, et al. Risk of cardiometabolic risk factors in women with and without a history of breast cancer: the pathways heart study. J Clin Oncol. 2022;40:1635-46.
75. Dong M, Wang R, Sun P, et al. Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs. Oncol Lett. 2021;21:315.
76. Gamble CR, Chen L, Szamreta E, Monberg M, Hershman D, Wright J. Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer. Arch Gynecol Obstet. 2022;305:1647-54.
77. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14:933-42.
78. Dickler MN, Barry WT, Cirrincione CT, et al. Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016;34:2602-9.
79. Cuppone F, Bria E, Vaccaro V, et al. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trials. J Exp Clin Cancer Res. 2011;30:54.
80. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245.
81. Lloyd-Sherlock P, Beard J, Minicuci N, Ebrahim S, Chatterji S. Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control. Int J Epidemiol. 2014;43:116-28.
82. Osude N, Durazo-Arvizu R, Markossian T, et al. Age and sex disparities in hypertension control: The multi-ethnic study of atherosclerosis (MESA). Am J Prev Cardiol. 2021;8:100230.
83. Holt E, Joyce C, Dornelles A, et al. Sex differences in barriers to antihypertensive medication adherence: findings from the cohort study of medication adherence among older adults. J Am Geriatr Soc. 2013;61:558-64.
84. Tamargo J, Rosano G, Walther T, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother. 2017;3:163-82.
86. Valenzuela PL, Carrera-Bastos P, Gálvez BG, et al. Lifestyle interventions for the prevention and treatment of hypertension. Nat Rev Cardiol. 2021;18:251-75.
87. Hinderliter AL, Smith P, Sherwood A, Blumenthal J. Lifestyle interventions reduce the need for guideline-directed antihypertensive medication. Am J Hypertens. 2021;34:1100-7.
88. Filippini T, Malavolti M, Whelton PK, Naska A, Orsini N, Vinceti M. Blood pressure effects of sodium reduction: dose-response meta-analysis of experimental studies. Circulation. 2021;143:1542-67.
89. Rainforth MV, Schneider RH, Nidich SI, Gaylord-King C, Salerno JW, Anderson JW. Stress reduction programs in patients with elevated blood pressure: a systematic review and meta-analysis. Curr Hypertens Rep. 2007;9:520-8.
90. Smith JR, Thomas RJ, Bonikowske AR, Hammer SM, Olson TP. Sex Differences in cardiac rehabilitation outcomes. Circ Res. 2022;130:552-65.
91. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J. 2005;26:1585-95.
92. Rosano GM, Lewis B, Agewall S, et al. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J. 2015;36:2677-80.
93. Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet. 1998;34:203-18.
94. Farkouh A, Riedl T, Gottardi R, Czejka M, Kautzky-Willer A. Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature. Adv Ther. 2020;37:644-55.
95. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143-57.
96. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499-523.
97. Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol. 2014;171:580-94.
98. Stolarz AJ, Rusch NJ. Gender differences in cardiovascular drugs. Cardiovasc Drugs Ther. 2015;29:403-10.
99. Freire AC, Basit AW, Choudhary R, Piong CW, Merchant HA. Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery. Int J Pharm. 2011;415:15-28.
100. Nicolas JM, Espie P, Molimard M. Gender and interindividual variability in pharmacokinetics. Drug Metab Rev. 2009;41:408-21.
101. Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health. 2005;14:19-29.
102. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002;41:329-42.
103. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther. 1999;66:594-601.
104. Walle T, Walle UK, Cowart TD, Conradi EC. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther. 1989;46:257-63.
105. Walle T, Byington RP, Furberg CD, McIntyre KM, Vokonas PS. Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther. 1985;38:509-18.
106. Krecic-Shepard ME, Park K, Barnas C, Slimko J, Kerwin DR, Schwartz JB. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther. 2000;68:130-42.
107. Krecic-Shepard ME, Barnas CR, Slimko J, Schwartz JB. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin Pharmacol Ther. 2000;68:286-92.
108. Dadashzadeh S, Javadian B, Sadeghian S. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm Drug Dispos. 2006;27:329-34.
110. Kajiwara A, Saruwatari J, Kita A, et al. Younger females are at greater risk of vasodilation-related adverse symptoms caused by dihydropyridine calcium channel blockers: results of a study of 11,918 Japanese patients. Clin Drug Investig. 2014;34:431-5.
